Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;36(21):e2311803.
doi: 10.1002/adma.202311803. Epub 2024 Apr 2.

Neutrophil Membrane-Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapy

Ya Zhao  1 , Qian Li  2 , Jingyan Niu  2 , Erliang Guo  3 , Chenchen Zhao  4 , Jian Zhang  5 , Xue Liu  6 , Lihua Wang  2 , Lang Rao  4 , Xiaoyuan Chen  7   8   9   10 , Kuikun Yang  1
Affiliations

Neutrophil Membrane-Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapy

Ya Zhao et al. Adv Mater. 2024 May.

Abstract

Neuroinflammation has emerged as a major concern in ischemic stroke therapy because it exacebates neurological dysfunction and suppresses neurological recovery after ischemia/reperfusion. Fingolimod hydrochloride (FTY720) is an FDA-approved anti-inflammatory drug which exhibits potential neuroprotective effects in ischemic brain parenchyma. However, delivering a sufficient amount of FTY720 through the blood-brain barrier into brain lesions without inducing severe cardiovascular side effects remains challenging. Here, a neutrophil membrane-camouflaged polyprodrug nanomedicine that can migrate into ischemic brain tissues and in situ release FTY720 in response to elevated levels of reactive oxygen species. This nanomedicine delivers 15.2-fold more FTY720 into the ischemic brain and significantly reduces the risk of cardiotoxicity and infection compared with intravenously administered free drug. In addition, single-cell RNA-sequencing analysis identifies that the nanomedicine attenuates poststroke inflammation by reprogramming microglia toward anti-inflammatory phenotypes, which is realized via modulating Cebpb-regulated activation of NLRP3 inflammasomes and secretion of CXCL2 chemokine. This study offers new insights into the design and fabrication of polyprodrug nanomedicines for effective suppression of inflammation in ischemic stroke therapy.

Keywords: anti‐inflammation; blood–brain barrier; ischemic stroke; nanomedicine; polyprodrug; scRNA‐seq.

PubMed Disclaimer

References

    1. a) C. W. Tsao, A. W. Aday, Z. I. Almarzooq, C. A. M. Anderson, P. Arora, C. L. Avery, C. M. Baker‐Smith, A. Z. Beaton, A. K. Boehme, A. E. Buxton, Y. Commodore‐Mensah, M. S. V. Elkind, K. R. Evenson, C. Eze‐Nliam, S. Fugar, G. Generoso, D. G. Heard, S. Hiremath, J. E. Ho, R. Kalani, D. S. Kazi, D. Ko, D. A. Levine, J. Liu, J. Ma, J. W. Magnani, E. D. Michos, M. E. Mussolino, et al., Circulation 2023, 147, e93;
    1. b) V. L. Feigin, B. A. Stark, C. O. Johnson, G. A. Roth, C. Bisignano, G. G. Abady, M. Abbasifard, M. Abbasi‐Kangevari, F. Abd‐Allah, V. Abedi, A. Abualhasan, N. M. E. Abu‐Rmeileh, A. I. Abushouk, O. M. Adebayo, G. Agarwal, P. Agasthi, B. O. Ahinkorah, S. Ahmad, S. Ahmadi, Y. Ahmed Salih, B. Aji, S. Akbarpour, R. O. Akinyemi, H. Al Hamad, F. Alahdab, S. M. Alif, V. Alipour, et al., Lancet Neurol. 2021, 20, 795;
    1. c) E. H. Lo, T. Dalkara, M. A. Moskowitz, Nat. Rev. Neurosci. 2003, 4, 399;
    1. d) M. A. Moskowitz, E. H. Lo, C. Iadecola, Neuron 2010, 67, 181.
    1. a) X. Wang, K. Tsuji, S.‐R. Lee, M. Ning, K. L. Furie, A. M. Buchan, E. H. Lo, Stroke 2004, 35, 2726;

MeSH terms

LinkOut - more resources